Bulk Drug Park + PLI: The 53 Critical APIs Reconciliation

A Tier-2 bulk-drug API manufacturer of the profile of Divi’s Laboratories — with a track record on the Bollaram and Vishakhapatnam campuses in Telangana and Andhra Pradesh — closes its scheme-entry documentation for a new Rs 550 crore Kakinada facility inside the Andhra Pradesh notified bulk-drug park under the parallel Department of Pharmaceuticals Scheme for Promotion of Bulk Drug Parks. The Kakinada facility is committed to manufacture three of the 53 critical Active Pharmaceutical Ingredients and Key Starting Materials identified under the DoP PLI Bulk Drug Rs 6,940 crore scheme — Penicillin G (the base beta-lactam antibiotic KSM), 7-Aminocephalosporanic Acid (7-ACA, a Cephalosporin intermediate KSM), and a Cephalosporin intermediate stream — all three fermentation-based Category A molecules that attract the 20 percent incentive rate for Years 1 through 4 under the PLI Bulk Drug scheme. This is Bulk Drug Park PLI 53 critical APIs reconciliation at operating scale for a Category A bulk-drug applicant, and the discipline that separates a defensible annual DoP claim from a scheme-level review is a molecule master keyed to the 53-critical-APIs list, a Category A versus Category B classification held at the DoP scheme level (not the applicant’s election), a capex-milestone matrix mapped to the DoP-set land-allotment / civil / commissioning / commercial-production timeline, an Andhra Pradesh notified bulk-drug-park land-allotment plot register, and a mutually exclusive election flag against the parallel PLI Pharma Rs 15,000 crore Category 2 KSM claim on the same molecule.

The reconciliation in one paragraph

A Category A bulk-drug applicant on the DoP PLI Bulk Drug Rs 6,940 crore scheme runs a five-surface reconciliation cascade. Surface one is the molecule master — the DoP-approved 53-critical-APIs list, each molecule tagged Category A (fermentation-based, 20 percent Years 1-4) or Category B (chemical-synthesis-based, 5 percent Years 1-4), with the per-molecule per-applicant maximum incentive cap held on file. Surface two is the mutually exclusive election flag — for each molecule the applicant confirms whether it has elected PLI Bulk Drug or PLI Pharma Category 2, so that no molecule can be double-claimed across the two parallel schemes. Surface three is the capex-milestone matrix — committed capex per molecule (illustratively of the order of Rs 400 to Rs 600 crore for a Category A fermentation-train molecule), capex incurred to date, capex-milestone dates for land allotment, civil construction, equipment installation and commissioning, and commencement of commercial production, and the incentive-year eligibility trigger tied to milestone achievement. Surface four is the Andhra Pradesh (or Himachal Pradesh or Gujarat) notified bulk-drug-park land-allotment register — plot number, allotment date, lease term, park-level common-utility interface, and the Ind AS 116 lease liability and right-of-use asset modelled against the plot lease. Surface five is the annual sales-value register per molecule at the applicable Category A or Category B rate with the per-molecule cap binding, feeding the Ind AS 20 grant recognition entry, the Section 115JB MAT book-profit adjustment, and the DoP annual claim workbook filing on the Department of Pharmaceuticals PLI portal.

What the scenario looks like in India — the illustrative persona

The PLI Bulk Drug Rs 6,940 crore scheme applicant universe is a narrower slice of the pharma sector than the PLI Pharma Rs 15,000 crore Category 2 applicant pool. The Category A (fermentation-based) applicant profile is dominated by API-heavy Tier-2 manufacturers with established fermentation capability — Divi’s Laboratories with its Hyderabad-Bollaram and Vishakhapatnam campuses (and the illustrative Kakinada bulk-drug-park build), Aurobindo Pharma with its Hyderabad API footprint (and its subsidiary Aurobindo Pharma Limited API division), Neuland Laboratories with its Hyderabad and Bonthapally sites, Laurus Labs with its Vishakhapatnam campus, Suven Pharmaceuticals with its Suryapet and Pashamylaram sites, and the API subsidiaries of the larger integrated formulators. The Category B (chemical-synthesis) applicant pool is broader — 41 chemical-synthesis molecules across therapy areas cover a wider set of applicants, including the API arms of Sun Pharma, Dr Reddy’s, Cipla, Lupin, Torrent, Zydus Lifesciences, Ipca Labs, and Alkem Labs.

For the illustrative worked example in this article, the persona is a Tier-2 bulk-drug applicant at the scale of Divi’s Laboratories committing a Rs 550 crore Kakinada facility inside the Andhra Pradesh notified bulk-drug park, targeting three Category A molecules (Penicillin G, 7-ACA, Cephalosporin intermediate stream). The persona is illustrative; real PLI Bulk Drug scheme selection lists, individual applicant capex commitments, and the DoP-approved per-molecule maximum incentive caps are disclosed in aggregate by the Department of Pharmaceuticals and are not the subject of speculative recomputation here. The point of the persona is the reconciliation surface, not the identity of any specific real applicant.

The three approved bulk-drug-park state locations under the parallel DoP Scheme for Promotion of Bulk Drug Parks are Andhra Pradesh (with the Kakinada bulk-drug-park node being the most visible), Himachal Pradesh (with a park node identified in the state’s northern industrial belt), and Gujarat (with a park node in the state’s chemical-manufacturing corridor). Each state’s park is a distinct land-allotment authority — the state’s industrial development corporation issues the plot allotment letter, and the applicant enters a lease agreement modelled under Ind AS 116 for the plot term. A multi-plot applicant with facilities in more than one notified park runs a distinct land-allotment register per park with plot-level reconciliation.

The regulatory overlay — PLI Bulk Drug scheme, Bulk Drug Park land scheme, mutual exclusion, Ind AS 20, Section 115JB MAT

Five regulatory anchors govern the PLI Bulk Drug claim and disbursement chain for a Category A applicant with an Andhra Pradesh bulk-drug-park plot, and each maps to a specific reconciliation surface.

The PLI Bulk Drug Rs 6,940 crore scheme guidelines, notified by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers, target 53 critical Key Starting Materials, Drug Intermediates and Active Pharmaceutical Ingredients for domestic manufacture. The scheme splits the 53 molecules into two rate categories: Category A (fermentation-based bulk drugs) at 20 percent of sales value for Years 1 through 4 with step-downs in later years, and Category B (41 chemical-synthesis molecules) at 5 percent of sales value for Years 1 through 4. Each molecule carries a per-selected-applicant maximum incentive cap. Selected applicants file an annual claim on the DoP portal supported by a statutory auditor certificate; the review cycle produces an approval, a query letter, or a partial disbursement decision within the DoP-published turnaround. The scheme requires committed capex — typically of the order of Rs 400 to Rs 600 crore per Category A fermentation-molecule cluster — with defined milestone dates that trigger the incentive-year eligibility.

The parallel Scheme for Promotion of Bulk Drug Parks is a distinct central-sector scheme with financial assistance to state governments for setting up common infrastructure facilities inside notified Bulk Drug Parks. Three states — Andhra Pradesh, Himachal Pradesh and Gujarat — have been notified as approved locations. The state provides the park-level land parcel and secures the environmental clearances at the park level; the participating manufacturer applies for a plot allotment inside the notified park and enters a lease agreement with the state industrial development corporation. The plot lease is modelled under Ind AS 116 as a right-of-use asset and a lease liability, with the lease term matching the plot allotment period. The applicant’s park-level common utility consumption — steam, chilled water, DM water, compressed air, effluent treatment, solvent recovery — is invoiced by the park utility operator against a metered consumption schedule.

Section 115JB of the Income-tax Act 1961 imposes Minimum Alternate Tax at 15 percent of book profit (plus surcharge and cess) where the tax computed under normal provisions is lower. The PLI Bulk Drug grant income is not currently listed as an exempt item that reduces book profit under Explanation 1 to Section 115JB — the grant increases book profit and correspondingly the MAT base. An applicant that has opted into the Section 115BAA concessional 22 percent regime is exempt from Section 115JB MAT altogether but is restricted from claiming the Section 35(2AB) R&D weighted deduction — materially valuable to a Category A applicant with an active fermentation-strain-development R&D pipeline at a DSIR-approved facility. The trade-off is a modelling input at scheme entry.

The mutually exclusive election rule between PLI Bulk Drug and PLI Pharma Category 2 is documented in the scheme guidelines and confirmed at the application stage. An applicant that has filed for PLI Bulk Drug on Penicillin G, 7-ACA, and Cephalosporin intermediates cannot also file for PLI Pharma Rs 15,000 crore Category 2 on those same molecules. A multi-product applicant may split its molecule portfolio across the two schemes — typically Category A fermentation molecules go to PLI Bulk Drug (where the 20 percent sales-value rate materially dominates the PLI Pharma 10 / 8 / 6 percent incremental-sales rate), and chemical-synthesis molecules outside the 41-molecule Category B list go to PLI Pharma Category 2. The election must be documented in a molecule master with the elected scheme flag per molecule, and no molecule can be double-flagged. The Section 92BA specified-domestic-transaction discipline for intra-group transfer of the identified molecule from the API applicant to a downstream Chapter 30 formulator sister entity — walked through in the API vs formulation HSN 2941 / 3003 / 3004 reconciliation guide and the backward integration API manufacturing transfer pricing walkthrough — is a parallel reconciliation surface that must feed the sales-value register with the arm’s-length treatment applied.

A worked example — a Category A applicant at Year 2 annual claim close

Illustrative — the following figures represent the operating pattern of a Category A PLI Bulk Drug applicant of the scale of a Tier-2 API manufacturer with a Rs 550 crore Kakinada bulk-drug-park facility. Public disclosures do not reveal per-molecule DoP-approved caps, per-applicant capex-milestone dates, or per-year sales-value bridges; the numbers below are illustrative of the reconciliation surface, not a claim about any specific real applicant’s PLI position.

The applicant enters the PLI Bulk Drug scheme with three DoP-approved Category A molecules: Penicillin G (per-molecule maximum incentive cap illustratively Rs 40 crore per year), 7-Aminocephalosporanic Acid (per-molecule cap Rs 35 crore per year), and a Cephalosporin intermediate stream (per-molecule cap Rs 25 crore per year). Aggregate per-year cap across the three molecules is Rs 100 crore. Committed capex on the Kakinada facility is Rs 550 crore, allocated Rs 250 crore to the fermentation train and Penicillin G downstream recovery, Rs 180 crore to the 7-ACA and Cephalosporin intermediate stream, and Rs 120 crore to shared plant utilities, effluent treatment, and civil construction inside the Andhra Pradesh notified bulk-drug park.

The capex-milestone matrix at end of Year 1 (FY 2020-21) shows land allotment achieved at Month 8 (Andhra Pradesh Industrial Infrastructure Corporation plot allotment letter dated illustratively 15 November 2020), civil construction milestone achieved at Month 22 (September 2022), equipment installation and commissioning achieved at Month 29 (April 2023), and commencement of commercial production achieved at Month 34 (September 2023). Year 1 incentive eligibility is deferred to Year 2 because commercial production commences in Year 3 relative to scheme-entry Year 1. Year 2 (FY 2021-22) and Year 3 (FY 2022-23) sales-value claims run against the illustrative per-molecule caps.

Year 2 annual claim workbook filed on the DoP portal shows:

On the accounting side, the Year 2 PLI grant receivable of Rs 95 crore is recognised under Ind AS 20 as reasonable assurance is established through the DoP portal filing and statutory auditor certificate; the applicant presents the grant as other income on the profit and loss statement per its accounting policy choice. Section 115JB MAT book-profit adjustment adds the Rs 95 crore grant to book profit for the year’s MAT provisioning. The Andhra Pradesh bulk-drug-park plot lease is modelled under Ind AS 116 with the right-of-use asset amortised over the 30-year plot lease term and the lease liability drawn down against the annual lease payment schedule. The DoP portal review cycle for the Year 2 filing produces approval within the DoP-published turnaround and the disbursement of Rs 95 crore is credited to the applicant’s designated bank account, matched against the receivable on ledger.

The mutually exclusive election flag per molecule is verified at the annual claim cycle — the molecule master confirms that Penicillin G, 7-ACA, and the Cephalosporin intermediate stream are elected for PLI Bulk Drug and are not double-flagged for PLI Pharma Category 2. Any other molecule that the applicant manufactures at a different site under a PLI Pharma Category 2 claim (an outside-the-53 chemical-synthesis KSM, for example) runs on the separate PLI Pharma Category 2 workbook walked through in the PLI Pharma Rs 15,000 crore eligibility and incremental sales reconciliation cornerstone.

Common reconciliation breakages

Five breakages recur across PLI Bulk Drug Category A claim runs, and each maps to a specific control failure.

• Category A vs Category B misclassification at molecule master setup. The DoP scheme holds the Category A / Category B classification at scheme level — Penicillin G is Category A (fermentation-based, 20 percent), and a specific chemical-synthesis KSM is Category B (chemical-synthesis, 5 percent). An applicant that mis-classifies a Category B molecule as Category A in its internal molecule master over-computes the incentive at 20 percent instead of 5 percent and files an inflated claim. The mis-classification surfaces at the DoP portal review and typically produces a query letter with a downward revision. Reconciliation discipline requires that the molecule master is populated from the DoP scheme document directly, not from the applicant’s internal categorisation, and any dispute is escalated to the DoP for scheme-level clarification before the claim is filed.

• Duplicate molecule claim across PLI Bulk Drug and PLI Pharma Category 2. A multi-product applicant that files for PLI Bulk Drug on some molecules and PLI Pharma Category 2 on others must ensure no molecule is double-flagged. A break — Penicillin G flagged for both PLI Bulk Drug and PLI Pharma Category 2 in the applicant’s internal molecule master — produces a duplicate claim that the DoP scheme rules explicitly bar. The break surfaces at the annual statutory auditor certificate cycle or at the DoP portal cross-reconciliation. The molecule master must carry a mutually exclusive election flag per molecule with a hard control that prevents both flags from being set.

• Capex-milestone slippage without corresponding incentive-year deferral. The scheme ties incentive-year eligibility to capex milestone achievement — land allotment, civil construction, equipment commissioning, and commencement of commercial production. An applicant that misses the commercial-production milestone in the scheme-year timeline but files a Year 2 claim against the original scheme-year mapping over-claims. The reconciliation discipline is a capex-milestone matrix with the achievement date per milestone and a hard control that binds the incentive-year eligibility to the actual milestone date, not the original scheme-year timeline.

• Andhra Pradesh bulk-drug-park plot lease not modelled under Ind AS 116. The plot allotment letter from the state industrial development corporation creates a right-of-use asset and a lease liability under Ind AS 116. An applicant that treats the plot as an operating lease and expenses the lease payment as a period cost under legacy AS 19 misstates the balance sheet. The Ind AS 116 discipline requires the right-of-use asset to be recognised at the present value of lease payments, amortised over the plot lease term, and the lease liability to be drawn down against the annual lease payment schedule. The reconciliation surface is a plot-level Ind AS 116 lease register keyed to the park plot number and the allotment date.

• Section 92BA intra-group transfer of the identified molecule to a downstream sister entity not documented under Rule 10D. A bulk-drug applicant that transfers Penicillin G to a downstream Chapter 30 formulator sister entity (typically an integrated group with an API arm and a formulation arm) triggers a Section 92BA specified domestic transaction. Rule 10D transfer-pricing documentation applies where the aggregate value exceeds the notified threshold. An applicant that treats the intra-group transfer as an ordinary intra-company transfer without Rule 10D documentation exposes itself to a transfer-pricing adjustment at the assessment cycle. The reconciliation surface is a Section 92BA specified-domestic-transaction register with the transfer volume, the arm’s-length benchmark, and the Rule 10D documentation reference — walked through in Terra Insight’s reconciliation failure-mode analysis for India methodology.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the DoP 53-critical-APIs list, the applicant’s ERP material master keyed to the molecule identifiers, the capex-milestone matrix per molecule, the Andhra Pradesh (or Himachal Pradesh or Gujarat) notified bulk-drug-park plot allotment register with the Ind AS 116 lease terms, and the annual sales-value ledger by molecule — and produces a per-molecule per-year sales-value bridge that closes the loop from ERP invoice line to DoP portal claim workbook. The platform applies the Category A 20 percent or Category B 5 percent incentive rate against sales value, binds the per-molecule per-applicant cap and explicitly quantifies the excess incentive foregone, tracks the mutually exclusive election flag against PLI Pharma Category 2 to prevent duplicate claims, generates the DoP portal annual claim workbook and the statutory auditor certificate template, and drives the Ind AS 20 grant receivable recognition entry with the Section 115JB MAT book-profit adjustment line and the Ind AS 116 plot-lease disclosure into the entity’s monthly close and annual tax provisioning workflow. Match rate improvement of 51 to 88 percent on the molecule-wise sales-value extraction and the DoP claim workbook reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform infrastructure for a Category A bulk-drug applicant with a multi-molecule, multi-park, multi-scheme claim stack. The commercial pillar for the sub-cluster is Pharma reconciliation software India; the broader authority is reconciliation software India.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 16 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024